Hyperprolactinemia

Hyperprolactinemia is defined as elevated serum prolactin concentration (>25 ng/mL in women, >20 ng/mL in men) resulting from dysregulation of the hypothalamic-pituitary axis or direct pituitary pathology. This condition is clinically significant because it represents the most common functional pituitary disorder and accounts for approximately 40% of all pituitary adenomas. With a prevalence of 0.4% in the general population and higher rates in women of reproductive age, hyperprolactinemia is routinely encountered in clinical practice and appears frequently on standardized examinations. The clinical importance lies in its diverse etiologies (ranging from medication-induced to life-threatening sellar masses), its impact on fertility and sexual function, and the potential for serious complications including apoplexy and vision loss from mass effect. Early recognition and appropriate investigation are essential to distinguish physiologic causes from pathologic processes requiring intervention.

Prolactin is uniquely controlled by tonic inhibition via dopamine, distinguishing it from other anterior pituitary hormones. The hypothalamus synthesizes dopamine in the tuberoinfundibular neurons, which travels through the hypothalamic-hypophyseal portal blood system to the anterior pituitary lactotroph cells. Dopamine occupies D2 receptors on lactotrophs, suppressing prolactin secretion and release. Any disruption of this inhibitory pathway—whether through destruction of dopaminergic neurons, interruption of portal blood flow, or pituitary pathology—results in unopposed prolactin production and hyperprolactinemia. This "disinhibition" principle explains why pituitary masses, even non-secreting adenomas compressing the pituitary stalk, cause elevated prolactin levels.

Dopamine D2 receptor antagonism or depletion of dopamine reduces the suppressive signal to lactotroph cells. Medications blocking D2 receptors (antipsychotics, metoclopramide) prevent dopamine from binding, causing unopposed lactotroph stimulation. This mechanism explains medication-induced hyperprolactinemia, which is entirely reversible upon drug discontinuation. The lactotrophs, sensing absence of dopamine's inhibitory signal, increase prolactin synthesis via enhanced transcription of the prolactin gene and increased secretion into the systemic circulation.

Any mass lesion occupying the sella turcica or compressing the pituitary stalk (prolactinoma, nonfunctioning adenoma, craniopharyngioma) disrupts the normal delivery of dopamine from the hypothalamus to anterior pituitary lactotrophs. This physical barrier prevents dopamine from reaching sufficient concentrations at the lactotroph surface, effectively removing tonic inhibition. Notably, prolactin levels typically remain <200 ng/mL with pure stalk compression, as some dopamine diffuses around the mass; higher levels suggest autonomous prolactin secretion by a prolactin-secreting adenoma. The stalk effect also causes secondary hypogonadism and other pituitary hormone deficiencies through reduced GnRH delivery.

Prolactinomas represent clonal proliferation of lactotroph cells, often arising from a somatic genetic alteration (most commonly loss of the tuberous sclerosis gene TSC2 or mutations affecting cAMP signaling). These adenomatous cells develop autonomous prolactin production independent of dopaminergic suppression, leading to marked prolactin overproduction. Lactotroph hyperplasia (without true adenoma formation) can occur with chronic dopamine antagonism or pregnancy-related physiologic stimulation, where the lactotroph population expands in response to estrogen-driven hyperplasia. Microadenomas (<10 mm) generally produce prolactin levels of 25-200 ng/mL, while macroadenomas (≥10 mm) frequently exceed 200 ng/mL.

Thyrotropin-releasing hormone (TRH) stimulation: TRH, released from the hypothalamus in response to hypothyroidism, stimulates lactotroph TSH receptors and thereby increases prolactin secretion. Hypothyroidism is a correctable cause of mild hyperprolactinemia, with prolactin typically 20-40 ng/mL.

Estrogen-mediated lactotroph hyperplasia: Physiologic elevation occurs during pregnancy due to estrogen stimulation of lactotroph proliferation and gene expression; prolactin levels increase 10-fold by term and remain elevated during lactation. Oral contraceptives and hormone replacement therapy cause mild prolactin elevation through similar estrogen-mediated mechanisms.

Reduced renal clearance: Prolactin is partially cleared by renal filtration; advanced chronic kidney disease or renal failure may cause prolactin accumulation, particularly important in dialysis patients.

Chest wall irritation: Herpes zoster, chest wall trauma, or thoracotomy triggers spinal afferent signals that stimulate hypothalamic TRH and prolactin release through a neurogenic mechanism.

Antipsychotics represent the most frequent pharmacologic culprits; typical antipsychotics (haloperidol, chlorpromazine) block D2 receptors with high affinity and consistently cause hyperprolactinemia. Atypical antipsychotics show variable effects: risperidone and paliperidone cause significant hyperprolactinemia comparable to typicals, while aripiprazole and quetiapine cause minimal elevation. Metoclopramide (antiemetic), domperidone, and other antiemetics act as D2 antagonists and frequently elevate prolactin. SSRIs can modestly elevate prolactin through multiple mechanisms including hypothalamic dysfunction and serotonin-dopamine interactions. Tricyclic antidepressants, venlafaxine, and other antidepressants occasionally cause elevation. Antihypertensives including methyldopa, reserpine, and verapamil deplete dopamine or block its effects. Opioids reduce dopamine tone. The duration and magnitude of elevation depend on drug potency and individual susceptibility; prolactin typically normalizes within weeks to months of drug discontinuation.

Prolactinomas account for 40-50% of functioning pituitary adenomas and represent the most common cause of pathologic hyperprolactinemia. These tumors show marked female predominance (female-to-male ratio approximately 10:1), typically present in women during reproductive years (20-50 years), and are usually diagnosed as microadenomas in women (who seek care for amenorrhea) but as macroadenomas in men (who present late with mass symptoms). Prolactin levels typically correlate with tumor size: microadenomas produce prolactin <200 ng/mL, while macroadenomas frequently exceed 200 ng/mL (occasionally >1000 ng/mL). Prolactinomas have excellent long-term prognosis with medical management; fewer than 5% undergo malignant transformation.

Hypothyroidism causes mild hyperprolactinemia (typically 20-40 ng/mL) through increased TRH stimulation of lactotrophs. This is a correctable cause; thyroid hormone replacement normalizes prolactin within 6-8 weeks. TSH screening is essential in every hyperprolactinemic patient.

Reduced renal clearance of prolactin, combined with accumulation of prolactin-stimulating factors, causes hyperprolactinemia proportional to the degree of renal dysfunction. This is particularly relevant in dialysis patients, where prolactin may reach 100+ ng/mL.

Herpes zoster affecting the thorax, post-thoracotomy status, or breast stimulation triggers neurogenic prolactin release through afferent spinal pathways. This mechanism explains why nipple stimulation in both men and women can acutely elevate prolactin and why thoracic shingles may present with hyperprolactinemia.

Physiologic lactotroph hyperplasia during pregnancy causes progressive prolactin elevation (10-fold increase by third trimester). Prolactin remains elevated during lactation and gradually normalizes after weaning. Pre-existing microprolactinomas may expand during pregnancy due to estrogen stimulation; macroadenomas carry risk of symptomatic expansion.

Physiologic doses of estrogen stimulate lactotroph proliferation and prolactin synthesis, causing prolactin elevation to 30-50 ng/mL. This elevation is generally mild and stable on continued hormone therapy.

Any mass lesion compressing the pituitary stalk causes the "stalk effect" resulting in hyperprolactinemia: nonfunctioning adenomas, craniopharyngiomas, meningiomas, germinomas, lymphoma, metastases, and inflammatory lesions (sarcoidosis, histiocytosis X). Hypopituitarism from any cause may present with relative hyperprolactinemia due to loss of other hormonal suppression.

After excluding medications, thyroid disease, renal failure, and mass lesions on MRI, approximately 10-20% of patients have no identifiable cause. Many have lactotroph hyperplasia or very small adenomas below MRI detection limits; some have mild functional disturbance. These patients require long-term follow-up but generally have excellent prognosis.

Elevated prolactin suppresses GnRH secretion and inhibits FSH and LH release, causing hypogonadotropic hypogonadism. In reproductive-aged women, this manifests as secondary amenorrhea (absence of menses for ≥3 months after normal menstrual history) or oligomenorrhea (infrequent menses). Prolactin levels >25 ng/mL may disrupt normal ovulation; amenorrhea is virtually universal when prolactin exceeds 100 ng/mL. The amenorrhea may be accompanied by anovulation, making pregnancy impossible. Many women present to gynecology with "infertility" before the underlying hyperprolactinemia is recognized.

Elevated prolactin directly stimulates lactotroph function, leading to inappropriate milk production from breast tissue. Galactorrhea may occur spontaneously or be expressed with manual breast compression; it occurs in men as well as women, though more commonly recognized in women. Galactorrhea correlates loosely with prolactin level but is not required for diagnosis; some patients with severe hyperprolactinemia lack galactorrhea. The presence of galactorrhea should always prompt prolactin measurement.

Hyperprolactinemia causes hypogonadism (reduced testosterone in men, reduced estrogen in women) through suppression of GnRH pulsatility. Men typically experience erectile dysfunction, decreased libido, and loss of spontaneous erections; women report decreased libido and vaginal dryness. This symptom complex is often the presenting complaint in men with prolactinomas, who frequently present later than women (often with macroadenomas) because amenorrhea is absent as a warning sign.

Both women and men may present with infertility as the primary concern. In women, anovulation due to suppressed GnRH prevents normal ovulation. In men, hypogonadism suppresses spermatogenesis and may cause azoospermia. Correction of hyperprolactinemia rapidly restores fertility in most cases.

Macroadenomas compressing surrounding structures cause headache (typically frontal and chronic, occasionally severe) and visual field defects. Compression of the optic chiasm from below causes superior bitemporal hemianopia (classically described but not always present). Vertical diplopia may occur with lateral extension compressing the oculomotor nerve. Visual defects are potentially reversible with tumor shrinkage during dopamine agonist therapy. Any patient presenting with these symptoms requires urgent MRI.

Spontaneous expression of milk from nipples (in non-pregnant, non-lactating patients) or milk present on examination confirms inappropriate prolactin action.

Prolonged hypogonadism causes breast tissue development in men and atrophy in women. In men, gynecomastia may be tender and may progress to significant volume.

Reduced facial/body hair, testicular atrophy (on palpation), or diminished virilization in men; vaginal dryness or atrophy in women.

Specific to macroadenomas with mass effect; ophthalmoplegia suggests lateral extension. Papilledema suggests elevated intracranial pressure from mass effect or hemorrhage.

Some patients, particularly older women and men, present without reproductive complaints but are found to have elevated prolactin during evaluation for other conditions (e.g., depression, obesity, pituitary MRI ordered for headache). These patients may have only mild elevation or may have adapted to chronic hypogonadism.

Some women maintain regular menses despite elevated prolactin, particularly when prolactin levels are only mildly elevated (25-50 ng/mL). This does not exclude diagnosis but suggests the elevation may be mild or intermittent.

Sudden hemorrhage or infarction within a prolactinoma (or other pituitary tumor) presents with acute severe headache, vision loss, ophthalmoplegia, altered mental status, and potential cardiovascular collapse. This is a medical emergency requiring urgent neurosurgical evaluation.

Prolactin should be measured from a fasting morning blood sample drawn 3-4 hours after waking, as prolactin shows diurnal variation with peak levels immediately upon waking and gradual decline through the day. Normal values are <25 ng/mL in women and <20 ng/mL in men, though some laboratories use slightly different reference ranges (typically 15-20 ng/mL for men, 20-25 ng/mL for women). A single elevated measurement warrants confirmation with repeat testing, as stress (from venipuncture itself, exercise, or other factors) can transiently elevate prolactin by 10-20 ng/mL. Persistent elevation on repeated measurement confirms hyperprolactinemia. A single dramatically elevated level (>200 ng/mL) is virtually diagnostic of prolactinoma; milder elevations require investigation for other causes. Macroprolactin (prolactin complexed with immunoglobulins) represents a potential pitfall; if clinical suspicion is low despite moderately elevated prolactin, testing for macroprolactin ("prolactin recovery after polyethylene glycol precipitation") may identify benign macroprolactinemia not requiring treatment.

Hypothyroidism is a correctable cause of hyperprolactinemia; TSH should be measured in every patient with elevated prolactin. TSH elevation indicates primary hypothyroidism, which causes mild prolactin elevation (typically 20-50 ng/mL) through increased TRH stimulation. Thyroid hormone replacement should be initiated, and prolactin should be rechecked in 6-8 weeks; persistent elevation after TSH normalization suggests an alternate etiology.

Chronic kidney disease impairs renal prolactin clearance. Serum creatinine >2.0 mg/dL or calculated GFR <30 mL/min/1.73m² suggests renal contribution to hyperprolactinemia; dialysis patients frequently have prolactin >100 ng/mL. Renal hyperprolactinemia typically plateau at moderate levels and are managed conservatively unless causing bothersome symptoms.

Pregnancy must be excluded, as it physiologically elevates prolactin